The significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations. Specifically, two viral vector-based vaccines [Vaxzervria (AstraZeneca; AZD1222) and COVID-19 . This table includes information on vaccines that have published phase 3 trial data in the peer reviewed literature and are provisionally approved by the Australian Government Therapeutic Goods Administration (TGA). The SARSCoV2 pandemic plagued the world over the course of the year. SARS-CoV-2 vaccine; cutaneous side-effects; infection; papulosquamous; skin diseases; vaccine hesitancy. In 4 patients PR appeared after the first vaccination; in one patient after the second one. Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature. As with eczema, the conditions can be differentiated under the microscope by their acanthotic or non-acanthotic appearance. sharing sensitive information, make sure youre on a federal Methods: Fortunately, PR-like eruption is responsive to topical corticosteroids without any systemic adverse effects. Chanprapaph K, Pomsoong C, Tankunakorn J, Eden C, Suchonwanit P, Rutnin S. Comparative analyses of clinical features, histopathology, and CD123 immunohistochemistry of oral lupus erythematosus, lichen planus, and other lichenoid lesions. Pityriasis rosea (PR) is an acute, exanthematous disease likely caused by human herpesvirus (HHV)-6 and/or HHV-7. (2020) 83:e5760. 2022 Nov-Dec;67(6):802-804. doi: 10.4103/ijd.ijd_562_22. PMC Bathe or shower in lukewarm water. Involvement of the oral mucosa has also been reported in as many as 50% of all cases (11). Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature JAAD Int. -. Epub 2022 Jan 5. doi: 10.1111/ijd.13061. Spongiotic dermatitis was the most commonly reported cutaneous reaction to COVID-19 vaccination among patients who also had biopsy results available for review, according to a registry-based. PRISMA, preferred reporting items for systematic reviews and metaanalysis. Unauthorized use of these marks is strictly prohibited. They described a patient developing pityriasis rosea (PR) 2 hours after the second dose of Moderna COVID-19 vaccination. In some cases, central hyperpigmentation was identified. We report 10 . Br J Dermatol. 2021 Aug;35(8):e491-e493. doi: 10.1111/jdv.17342. Although the exact pathophysiologic mechanisms of PR after vaccination remain unclear, immune responses to COVID-19 vaccines and disruption of T-cell mediated control of latent infections were implicated (12, 1518). However, the etiopathogenetic mechanisms remain largely unknown and further studies are needed in order to clarify the correlation between SARS-CoV-2 and PR. The https:// ensures that you are connecting to the The duration of the infection ranges from two weeks to three months. Please enable it to take advantage of the complete set of features! HHS Vulnerability Disclosure, Help government site. (2021) p. e15040. Epub 2021 Nov 2. The experience on a case of Pityriasis Rosea diagnosed after Covid 19 infection with atypical clinical presentation and low responsiveness to conventional treatments is shared. The site is secure. 2021;184(6):11941195. It is possible that a relationship anti- Sars-CoV-2 vaccinationPR/PRLE exists; however, it is very rare, in consideration of millions of vaccinated subjects and the low number of reported cases with PR/PRLE. Unauthorized use of these marks is strictly prohibited. Dear Editor, Pityriasis rosea (PR) is a common, self-limited erythematous papulosquamous dermatosis that mainly affects young adults. But some patients also are developing delayed skin reactions on. eCollection 2022 Jul. Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. But once it's gone, it doesn't come back. Keywords: But there are important differences between these 2 conditions. Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination 8600 Rockville Pike However, in cases of atypical PR, it may present with erythema multiforme-like lesions and purpura (5). Bookshelf Data were independently extracted and accessed for bias. Reply to "the significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations" by Ciccarese G. et al. COVID-19 has been reported as one such viral trigger for PR. FOIA We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. The disease begins with a single erythematous plaque, the so-called herald patch that usually appears on the trunk: it is roundish, pink to red in color and remains the only clinical manifestation for some days, when widespread, clinically similar, although smaller lesions appear. This article presents a case of PR in a 66-year-old black male 1 week after administration of the Pfizer-BioNTech COVID-19 vaccine. -, Broccolo F., Drago F., Careddu A.M., et al. sharing sensitive information, make sure youre on a federal Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. New urticaria in the weeks after COVID-19 vaccination (March 2023) OTHER DERMATOLOGY. Six days later, she developed a rash on her. government site. To the best of our knowledge, only one case of ChAdOx1 nCoV-19 vaccine-induced PR-like eruption has been reported (2). Epub 2021 Sep 25. Accessibility Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. The. The https:// ensures that you are connecting to the Epub 2022 Jul 19. 8600 Rockville Pike J Am Acad Dermatol. Bethesda, MD 20894, Web Policies Department of Dermatology, Graduate School of Medicine, Kyusyu University, Japan. As the worldwide vaccination campaign against the COVID19 pandemic continues, we emphasize that pityriasis rosea can result from new CoronaVac COVID19 vaccine, for both physicians and patients, and lesions may be reactivated after the second vaccination. 2022 Nov 6;15:2369-2382. doi: 10.2147/CCID.S388245. Cutis. (2021) 85:4655. Veraldi S, Boneschi V, Cusini M, Maronese CA. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Federal government websites often end in .gov or .mil. Pityriasis rosea developing after COVID19 vaccination. doi: 10.1016/j.jaad.20.2103.092. doi: 10.1111/bjd.20143. +39.3465909404. Curr Dermatol Rep. 2022;11(4):289-312. doi: 10.1007/s13671-022-00370-9. Clipboard, Search History, and several other advanced features are temporarily unavailable. Previously, PR has been reported in temporal association with various viral inoculations. All patients were treated with cetirizine (20 mg/day for 7-14 days). KL and KP collated resources. Apply a moisturizer, calamine lotion or a nonprescription . Pityriasis rosea is a common rash that usually begins as a round or oval-shaped patch and spreads in stages in a characteristic pattern. 2022 Jan;114:88-89. doi: 10.1016/j.ijid.2021.10.055. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations. These types cannot cause cold sores or genital herpes. Keywords: adverse effect, coronavirus, cutaneous eruptions, immunization, pityriasis rosea, SARS-CoV-2, vaccine, case report, Citation: Leerunyakul K, Pakornphadungsit K and Suchonwanit P (2021) Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination. 2021 Aug;185(2):e34. 2022 May;35(5):e15391. Epub 2021 Jun 10. 8:752443. doi: 10.3389/fmed.2021.752443. Histopathological Spectrum of Cutaneous Reactions following COVID-19 Vaccine - An Observational Study. It often presents with diffuse and confluent severely pruritic dusky-red erythematous lesions in the absence of herald patch (11). They suggested that the short time elapsed between vaccination and PR onset resembled that of delayed localized cutaneous reactions occurring shortly after the second vaccine dose. In the period May 2021- February 2022 we observed five cases of clinically typical PR that appeared 2 to 3 weeks after anti-SARS-CoV-2 vaccination with BNT162b2 (3 patients) or mRNA- 1273 (2 patients). Atzori L, Pinna AL, Ferreli C, Aste N. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review. In 3 patients a biopsy for histopathological examinations was carried out. Veraldi S, Boneschi V, Cusini M, Maronese CA. 2022 May;121(5):1003-1007. doi: 10.1016/j.jfma.2021.12.028. Bethesda, MD 20894, Web Policies Table 1 summarizes all reported cases of PR-like eruption following COVID-19 vaccination. Epub 2022 Jan 31. However, pityriasis rosea is a selflimiting benign exanthema and does not require . Br J Dermatol. Xing K, Tu XY, Liu M, et al. Bin Rubaian NF, Almuhaidib SR, Aljarri SA, Alamri AS. We observed Covid: Skin rashes are ONLY symptom for 21% patients, says KCL study Keywords: Cazzato G, Ambrogio F, Foti C, Capuzzolo M, Trilli I, Casatta N, Lupo C, Carrieri M, Daini D, Colagrande A, Maiorano E, Ingravallo G. Diagnostics (Basel). PR is a common self-limited papulosquamous eruption typically presenting with a large solitary pink-colored patch or plaque (i.e., herald patch), followed by secondary eruptions of smaller erythematous patches or plaques with associated peripheral collarette scaling distributed along the cleavage lines of the trunk, forming a Christmas tree pattern (5). (2021) 35:e5468. Veraldi S, Boneschi V, Cusini M, Maronese CA. Accessed February 2, 2022. Children often get infected when someone sneezes or kisses them. Polack FP, Thomas SJ, Kitchin N et al. Itching is often mild. If so, the reason may be simple: in several countries, BNT162b2 is the most used vaccine; iii) in 55 cases the rash was classified as PR, in 6 cases as PRLE; iv) in 39 cases the eruption appeared 1-12 days after the first dose (around: 4.8 days). All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. The mechanisms behind these COVID-19-related symptoms remain unclear. 2021;35(8):e489e491. However, some hypotheses may be advanced: PR/PRLE following anti-Sars-CoV-2 vaccination may be just a coincidence; anti-Sars-CoV-2 vaccines cause a reactivation of HHV-6 and/or HHV-7; vaccines can induce a delayed hypersensitivity response clinically similar to drug-induced PRLE. JAAD Case Rep 2018; 4:8001. Many Americans become infected with them at an early age.